FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379511137> ?p ?o ?g. }

• W4379511137 endingPage "313" @default.
• W4379511137 startingPage "312" @default.
• W4379511137 abstract "Background Few studies have addressed what is the optimal therapeutic option in patients with rheumatoid arthritis (RA) who failed treatment with JAK inhibitors (JAKi). Objectives The aim of this study was to evaluate the drug retention, efficacy, and safety of biologics or JAKi in patients who showed an inadequate response to JAKi in a multicenter longitudinal cohort. Methods Patients who showed an inadequate response to JAKi and then switched to TNF inhibitors [TNFi], IL-6 inhibitors [IL-6i], or other JAKi were enrolled in this study. The drug retention rates of the three treatment groups were estimated at 12 months using the Kaplan-Meier method and compared after adjusting for potential confounders using Cox proportional hazards models. Disease activities evaluated with Clinical Disease Activity Index (CDAI) were also compared at 1, 3, 6, and 12 months between the three groups using the Mann-Whitney U test or the Wilcoxon signed-rank test. The reasons for drug discontinuation were analyzed using Fisher’s exact test. Results A total of 140 treatment courses (TCs) from 106 patients were included (TNFi: 36 TCs, IL-6i: 34 TCs, and JAKi: 70 TCs). Baseline characteristics showed no difference in sex, disease duration, number of previous biologics/JAKi use, and ACPA positivity between the three groups, but the concomitant PSL dose was significantly lower in the JAKi group than in other groups (P=0.049). After adjusting potential confounders, drug retention rates of the three treatment groups did not differ; however, when limited to patients who initiated subsequent biologics/JAKi within 100 days after the termination of prior treatment with JAKi, the TNFi group exhibited a superior drug retention rate compared to the JAKi group (P=0.048, Figure 1A-1C). Regarding disease activity, the baseline CDAI of the TNFi group was significantly higher than the other groups (P=0.01, Figure 1D, 1E); however, the TNFi group tended to show better improvement in disease activity than the other groups. The reasons for drug discontinuation were not different between the three groups. Conclusion TNFi may have a therapeutic advantage compared to other therapeutic options in patients who failed treatment with JAKi. Figure 1. (A) Comparison of drug retention between JAKi and TNFi. (B) Comparison of drug retention between JAKi and IL-6i. (C) Comparison of drug retention between TNFi and IL-6i. (D) Time course of mean CDAI in the three treatment groups. (E) Time course of CDAI improvement compared in the three treatment groups. TNFi, TNF inhibitors; IL-6i, IL-6 inhibitors; JAKi, JAK inhibitors; CDAI, Clinical Disease Activity Index. Acknowledgements I have no acknowledgments to declare. Disclosure of Interests Naofumi Yoshida: None declared, Ryu Watanabe Speakers bureau: Asahi Kasei, Chugai, Eli Lilly, GSK, and Sanofi, Grant/research support from: AbbVie, Wataru Yamamoto: None declared, Kosaku Murakami: None declared, Koichi Murata Speakers bureau: AbbVie GK, Eisai Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Bristol-Myers Squibb, Daiichi Sankyo Co. Ltd., and Asahi Kasei Pharma Corp, Kenichiro Hata: None declared, Tohru Takeuchi Speakers bureau: Asahi Kasei Pharma, Mitsubishi Tanabe Pharma, Taisho Pharmaceutical, Chugai Pharmaceutical, Eisai, Boehringer Ingelheim, Abbie, AstraZeneca, Bristol-Myers, Consultant of: Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Grant/research support from: Asahi Kasei Pharma, Mitsubishi Tanabe Pharma, Taisho Pharmaceutical, Chugai Pharmaceutical, Eisai, Novartis Pharma, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Yuki Etani: None declared, Yasutaka Okita Speakers bureau: Chugai Pharmaceutical, Pfizer, and Ono Pharmaceutical., Yonsu Son: None declared, Hideki Amuro: None declared, Hirotaka Yamada: None declared, Yo Ueda: None declared, Ryota Hara Shareholder of: AbbVie, Eisai, Yoshio Ozaki: None declared, Tomoki Ito Grant/research support from: Asahi Kasei Pharma, Motomu Hashimoto Speakers bureau: Eli Lilly Japan, Chugai Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Bristol-Myers, Eisai Co., Grant/research support from: AbbVie, Asahi Kasei Pharma, Astellas Pharma Inc., Bristol-Myers, Eisai Inc., Daiichi Sankyo Company, Limited, Eli Lilly Japan., Novartis Pharma." @default.
• W4379511137 created "2023-06-07" @default.
• W4379511137 creator A5002284882 @default.
• W4379511137 creator A5014950876 @default.
• W4379511137 creator A5018092891 @default.
• W4379511137 creator A5028383119 @default.
• W4379511137 creator A5028875915 @default.
• W4379511137 creator A5031860797 @default.
• W4379511137 creator A5039685784 @default.
• W4379511137 creator A5040347971 @default.
• W4379511137 creator A5042491943 @default.
• W4379511137 creator A5051109631 @default.
• W4379511137 creator A5055194718 @default.
• W4379511137 creator A5058628871 @default.
• W4379511137 creator A5073839222 @default.
• W4379511137 creator A5076008841 @default.
• W4379511137 creator A5078572977 @default.
• W4379511137 creator A5082256584 @default.
• W4379511137 creator A5086225100 @default.
• W4379511137 date "2023-05-30" @default.
• W4379511137 modified "2023-09-27" @default.
• W4379511137 title "POS0176 DRUG RETENTION OF BIOLOGICS OR JAKI IN RHEUMATOID ARTHRITIS PATIENTS WHO FAILED TREATMENT WITH JAKI: RESULTS FROM THE ANSWER COHORT" @default.
• W4379511137 doi "https://doi.org/10.1136/annrheumdis-2023-eular.979" @default.
• W4379511137 hasPublicationYear "2023" @default.
• W4379511137 type Work @default.
• W4379511137 citedByCount "0" @default.
• W4379511137 crossrefType "journal-article" @default.
• W4379511137 hasAuthorship W4379511137A5002284882 @default.
• W4379511137 hasAuthorship W4379511137A5014950876 @default.
• W4379511137 hasAuthorship W4379511137A5018092891 @default.
• W4379511137 hasAuthorship W4379511137A5028383119 @default.
• W4379511137 hasAuthorship W4379511137A5028875915 @default.
• W4379511137 hasAuthorship W4379511137A5031860797 @default.
• W4379511137 hasAuthorship W4379511137A5039685784 @default.
• W4379511137 hasAuthorship W4379511137A5040347971 @default.
• W4379511137 hasAuthorship W4379511137A5042491943 @default.
• W4379511137 hasAuthorship W4379511137A5051109631 @default.
• W4379511137 hasAuthorship W4379511137A5055194718 @default.
• W4379511137 hasAuthorship W4379511137A5058628871 @default.
• W4379511137 hasAuthorship W4379511137A5073839222 @default.
• W4379511137 hasAuthorship W4379511137A5076008841 @default.
• W4379511137 hasAuthorship W4379511137A5078572977 @default.
• W4379511137 hasAuthorship W4379511137A5082256584 @default.
• W4379511137 hasAuthorship W4379511137A5086225100 @default.
• W4379511137 hasBestOaLocation W43795111371 @default.
• W4379511137 hasConcept C126322002 @default.
• W4379511137 hasConcept C191093355 @default.
• W4379511137 hasConcept C2777575956 @default.
• W4379511137 hasConcept C2778715236 @default.
• W4379511137 hasConcept C71924100 @default.
• W4379511137 hasConcept C72563966 @default.
• W4379511137 hasConceptScore W4379511137C126322002 @default.
• W4379511137 hasConceptScore W4379511137C191093355 @default.
• W4379511137 hasConceptScore W4379511137C2777575956 @default.
• W4379511137 hasConceptScore W4379511137C2778715236 @default.
• W4379511137 hasConceptScore W4379511137C71924100 @default.
• W4379511137 hasConceptScore W4379511137C72563966 @default.
• W4379511137 hasIssue "Suppl 1" @default.
• W4379511137 hasLocation W43795111371 @default.
• W4379511137 hasOpenAccess W4379511137 @default.
• W4379511137 hasPrimaryLocation W43795111371 @default.
• W4379511137 hasRelatedWork W2082406232 @default.
• W4379511137 hasRelatedWork W2156283049 @default.
• W4379511137 hasRelatedWork W2316954211 @default.
• W4379511137 hasRelatedWork W2322691686 @default.
• W4379511137 hasRelatedWork W2326094713 @default.
• W4379511137 hasRelatedWork W2427075784 @default.
• W4379511137 hasRelatedWork W2427452099 @default.
• W4379511137 hasRelatedWork W2761967325 @default.
• W4379511137 hasRelatedWork W2766844642 @default.
• W4379511137 hasRelatedWork W4245782456 @default.
• W4379511137 hasVolume "82" @default.
• W4379511137 isParatext "false" @default.
• W4379511137 isRetracted "false" @default.
• W4379511137 workType "article" @default.